Key result
Epicardial sustained-release of hepatocyte growth factor using gelatin hydrogel sheets significantly improved fractional shortening at 2 weeks compared to normal saline (48.6% vs 24.8%, P<0.01).
Why the study?
Does epicardial sustained-release of HGF improve cardiac function in a chronic myocarditis rat model?
Does epicardial sustained-release of HGF improve cardiac function in a chronic myocarditis rat model?
Absolute Event Rate: 48.6% vs 24.8%
p-value: p=< 0.01
Sustained-release of HGF via gelatin hydrogel sheets improves cardiac function and reduces fibrosis and apoptosis in a rat model of chronic myocarditis.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use in myocarditis; hypothesis-generating for sustained-release HGF in inflammatory cardiomyopathy.
Nakano et al. (2013) studied Autoimmune myocarditis. Epicardial sustained-release of hepatocyte growth factor (HGF) using gelatin hydrogel sheets vs. Normal saline-incorporated gelatin hydrogel sheets (G-NS) and Control was evaluated on Fractional shortening at 2 weeks (p=< 0.01). Epicardial sustained-release of hepatocyte growth factor using gelatin hydrogel sheets significantly improved fractional shortening at 2 weeks compared to normal saline (48.6% vs 24.8%, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: